EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors

Takeshi Kondo iD, Eri Matsuki, Tomoiku Takaku, Naoki Watanabe, Chikashi Yoshida, Masaya Okada, Kazunori Murai, Takashi Kodama, Naoto Takahashi, Shinya Kimura, Itaru Matsumura, Preg‐CML/Japan Study Investigators

Cancer · 2025-01 · 131 (1)

DOI: 10.1002/cncr.35611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 30.10.2024. Verfasst von Takeshi Kondo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Blood Disorders Center, Aiiku Hospital, Sapporo, Hokkaido, Japan. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Pregnancy Outcome, Pregnancy Complications, Neoplastic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer Health Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Young female patients with chronic myeloid leukemia (CML) often face challenges becoming pregnant due to the teratogenicity of tyrosine kinase inhibitors (TKIs).

Methods

The authors conducted a nationwide survey of female patients with CML who experienced pregnancy between 2002 and 2020.

Results

Information for 70 pregnancies in 49 patients was obtained. There were three types of pregnancies: CML onset during pregnancy ( n = 9), unplanned pregnancy mostly during treatment with a TKI ( n = 25), and planned pregnancy during treatment‐free remission (TFR) or treatment with interferon‐alpha (IFN‐α) ( n = 36). The median duration from CML diagnosis to pregnancy in patients with planned pregnancy was significantly longer than that in patients with unplanned pregnancy (10.6 years vs. 4.1 years, p < .001). In 48 pregnancies that resulted in childbirth, TFR and treatment with IFN‐α were chosen in 26 and 17 pregnancies, respectively. Sustained major or deeper molecular response was observed in 18 of 26 pregnancies with TFR. The patients who fulfilled the requirements for TKI therapy discontinuation by European LeukemiaNet recommendations achieved a TFR rate of 77% in pregnancy. Treatment with IFN‐α might be effective for patients who are in complete cytogenetic response or deeper response (response rate, 76%).

Conclusion

Pregnancy by TFR or treatment with IFN‐α could be a safe and feasible way for patients with CML. However, a substantial duration of treatment with a TKI before conception may be needed for planned pregnancy. Planning and evaluation for pregnancy should be considered at the time of CML onset for female patients with childbearing potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsPregnancy OutcomePregnancy Complications, NeoplasticInterferon-alphaHumansFemalePregnancyAdultYoung AdultAdolescentTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

chronic myeloid leukemiainterferon‐alphapregnancytreatment discontinuationtreatment‐free remissiontyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsInterferon-alphaTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Blood Disorders Center, Aiiku Hospital, Sapporo, Hokkaido, Japan.
  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Hematology, Saitama Medical University, Iruma district, Saitama, Japan.
  • Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
  • Department of Hematology, NHO Mito Medical Center, Ibaraki, Japan.
  • First Department of Internal Medicine, Kansai Medical University Medical Center, Moriguchi, Osaka, Japan.

ORCID-Profile: Takeshi Kondo

Förderung

  • Pfizer Health Research Foundation

Zitieren

APA

Kondo, T., Matsuki, E., Takaku, T., Watanabe, N., Yoshida, C., Okada, M., Murai, K., Kodama, T., Takahashi, N., Kimura, S., Matsumura, I., & Preg‐CML/Japan Study Investigators (2025). Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Cancer, 131(1). https://doi.org/10.1002/cncr.35611

Vancouver

Kondo T, Matsuki E, Takaku T, Watanabe N, Yoshida C, Okada M, et al. Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Cancer. 2025;131(1). doi:10.1002/cncr.35611

BibTeX
@article{Kondo2025,
  author = {Kondo, Takeshi and Matsuki, Eri and Takaku, Tomoiku and Watanabe, Naoki and Yoshida, Chikashi and Okada, Masaya and Murai, Kazunori and Kodama, Takashi and Takahashi, Naoto and Kimura, Shinya and Matsumura, Itaru and Preg‐CML/Japan Study Investigators, Preg‐CML/Japan Study Investigators},
  title = {Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {1},
  doi = {10.1002/cncr.35611}
}
Kostenlos starten →